Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma

BACKGROUND: Tumor mutation burden (TMB) as estimated by cancer gene panels (CGPs) has been confirmed to be associated with prognosis and is effective in predicting clinical benefit from immune checkpoint blockade (ICB) in solid tumors. However, whether the TMB calculated by CGPs is associated with o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Cunte, Liu, Sichu, Jiang, Xinmiao, Huang, Ling, Chen, Feili, Wei, Xiaojun, Guo, Hanguo, Shao, Yang, Li, Yangqiu, Li, Wenyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962318/
https://www.ncbi.nlm.nih.gov/pubmed/33722306
http://dx.doi.org/10.1186/s40164-021-00215-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962318/
https://www.ncbi.nlm.nih.gov/pubmed/33722306
http://dx.doi.org/10.1186/s40164-021-00215-4

Ejemplares similares